Global High Dose Rate (HDR) Brachytherapy Market Overview:
High dose rate brachytherapy is also known as temporary brachytherapy. In Brachytherapy, which is a type of internal radiotherapy, the tubes are inserted into the prostate gland and a source of radiation is passed to destroy the cancer cells. When HDR brachytherapy taken together with external beam radio therapy, the individual with medium to high risk prostate cancer gets a higher dose. It has various advantages such as lesser time required for treatment, quick recovery, and low risk of side effects. According to the World Health Organization, 70% fatalities related to cancer occur in low and middle income countries.
- Wide range of applications are of HDR brachytherapy is driving the market. These include, low risk, minimal side effects and lesser time required for treatment.
- Increased adoption of radiotherapy by physicians
- Availability of other treatments for cancer
- Technological developments along with Research and developments initiatives
- Rising number of cases associated with cancer
- Side effects and Risks with HDR brachytherapy may hinder the market
Some of the key players profiled in the report are Eckert & Ziegler BEBIG (Germany), IsoRay Medical, Inc. (United States), Elekta AB (Sweden), Varian Medical Systems, Inc. (United States), Lumitos AG (Germany), C.R Bard Inc. (United States), Argon Medical Devices (United States) and IsoAid (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global High Dose Rate (HDR) Brachytherapy market by 2025. Considering Market by , the sub-segment i.e. will boost the High Dose Rate (HDR) Brachytherapy market.
In May 2019, Varian Medical Systems has signed an agreement to acquire CTSI. This acquisition is expected to boost the identification of unmet clinical and operational needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global High Dose Rate (HDR) Brachytherapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in High Dose Rate (HDR) Brachytherapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.